Prevalence, incidence and mortality of interstitial lung disease in patients with Sjogren disease: data from the prospective observational "EMERGE" study

Rheumatoid Arthritis

Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study

Arthritis Res Ther

Östör A, Feist E, Sidiropoulos P, Avouac J, Rebella M, Namas R, McDearmon-Blondell E, Gao T, Lagunes-Galindo I, Strengholt S, Zisman D, Attar S

doi: 10.1186/s13075-025-03528-5

RECOMMENDED

Systemic Sclerosis

Systemic Sclerosis-Associated Interstitial Lung Disease: What We Know and How to Incorporate Guidelines into Clinical Practice

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Chest

Esposito AJ, Selvan KC, Richardson C, Khanna D, Bemiss BC, Bernstein EJ, Chung JH, Cox CW, Dematte JE, Denton CP, Distler O, Hinchcliff ME, Smith V, Strek ME, Varga J, Hoffmann-Vold AM, Volkmann ER

doi: 10.1016/j.chest.2025.11.047

Immunodeficiency

A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary Immunodeficiency

J Clin Immunol

Lumry WR, Palumbo M, Hsu C, Hussain I, McNeil D, Bridges T, Wedner HJ, Scarupa M, Mondou E, Nanaware-Kharade N, Hanna K, Coll MQ, Oliveras J

doi: 10.1007/s10875-025-01952-5

Psoriasis

Bimekizumab efficacy and safety in Chinese patients with psoriasis in the BE SHINING Phase 3 study

J Eur Acad Dermatol Venereol

Cai L, Man XY, Wang J, Wei A, Chen Y, Deherder D, Gao J, Hoepken B, Sun W, Lei T, Zhang J, BE SHINING Study Group

doi: 10.1111/jdv.70350

Psoriasis

Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasis

J Eur Acad Dermatol Venereol

Merola JF, Guenther L, Lynde C, Papp KA, Parish LC, Yamauchi P, Cheng S, Amouzadeh H, Deignan C, Jardon S, Chen M, Pinter A

doi: 10.1111/jdv.70110

Autoimmune Disease

Development and Validation of a Disease Severity Index for Patients with Cold Urticaria

J Allergy Clin Immunol Pract

Altunergi T, Pereira MP, Altrichter S, Gutsche A, Ahsan DM, Fox Cand L, Grekowitz E, Bonnekoh H, Weller K, Maurer M, Salameh P, Terhorst-Molawi D

doi: 10.1016/j.jaip.2025.04.047

Rheumatoid Arthritis

Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

Ann Rheum Dis

Taylor PC, Mease PJ, de Vlam K, Mpofu S, Wetzel D, Stevens AM, Wiens B, Koskinen LO, Ohlman S, Feldwisch J, Frejd FY, Brun NC, Brandt-Juergens J, Drescher E, Dokoupilova E, Rowińska-Osuch A, Abdel-Kader Martin N, Behrens F

doi: 10.1016/j.ard.2025.02.019

Systemic Lupus Erythematosus

Effects of sodium-glucose transporter 2 inhibitors in patients with lupus nephritis: a before-and-after retrospective cohort study

Rheumatology (Oxford)

Ramírez-Mulhern I, Navarro-Sánchez V, Rivero-Otamendi E, Sánchez-Mejía DE, Zavala-Miranda MF, Mejia-Vilet JM

doi: 10.1093/rheumatology/keaf548

Atopic Dermatitis

Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage)

Br J Dermatol

Warren RB, de Bruin-Weller M, Tsianakas A, Khemis A, Szepietowski JC, Hong HC, Mihaylov Y, Falqués M, Agell H, Massana E, Gil EG, Coll R, Weidinger S

doi: 10.1093/bjd/ljaf285

Related content